Articles

September 14, 2020 Navigating AHP and Pain During a Pandemic As the COVID-19 pandemic continues to have a significant impact on people and communities around the world, it poses unique challenges for people living with AH Read More ›
September 2, 2020 With Innovation in Market Access, European Patients Can Fully Experience Biotech’s Transfo ... What’s needed is a larger measure of creativity, flexibility and coordination around market access. This must become the new baseline environment in which Europ Read More ›
August 6, 2020 Alnylam Promotes Dr. Yvonne Greenstreet to President & COO Dr. Yvonne Greenstreet, has been elevated to the role of President of Alnylam. She will retain her COO role as well. Read More ›
August 3, 2020 How to Evaluate a Medicine for the Treatment of an Ultra-rare Disease Such as PH1 For a new medicine to become available, it needs to undergo stringent testing in clinical trials to evaluate its safety and, importantly, its efficacy (how well Read More ›
June 24, 2020 Celebrating a Pride Month Unlike Any Other We asked members of our SAGA (Sexuality and Gender Alliance) employee resource network (ERN) how they've been celebrating Pride this year, given the Read More ›
June 15, 2020 Rethinking R&D to Prime it for Future Success Much of the world has this romantic notion that drug discovery involves a small numbers of hero scientists toiling away in a lab until – Eureka! – the breakthro Read More ›
June 9, 2020 John Maraganore in "Biotechnology in the Time of COVID-19: Commentaries from the Front Lin ... In a new e-book, dozens of biopharma industry leaders, including our CEO John Maraganore, share their perspectives from the industry's unique vantage point on t Read More ›
June 7, 2020 Alnylam Leaders at BIO International Convention 2020/"Digital BIO" Even though the BIO International Convention has gone virtual for 2020 as a result of COVID-19, Alnylam leaders will continue to contribute to the informative, Read More ›
June 2, 2020 Announcing the 2019-2020 Advocacy for Impact Grant Recipients The Alnylam 2019-2020 Advocacy for Impact grant recipients come from five countries across three continents, and will receive grants totaling USD $270,000.00... Read More ›
June 1, 2020 We Stand Against All Forms of Racism and Discrimination On June 1, 2020, we issued the following public statement in response to events unfolding in the United States as a result of the killing of George Floyd and Read More ›

Get In Touch

Have any questions or comments about the content you see on this page?

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site